Is Adial Pharmaceuticals, Inc. (ADIL) a Buy, Sell, or Hold?
NASDAQ : ADIL
Adial Pharmaceuticals, Inc.
$3.339 USD
$0.19 (6.0%)
- Volume
- 28.09K
- Average Volume
- 460.17K
- Market Capitalization
- $3.2M
- P/E Ratio
- -0.34
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $12.00
- Year Low
- $1.31
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.18
Company Overview
NASDAQ
Cary John Claiborne
Biotechnology
Healthcare
ADIL
5
US
USD
Liquidity Metrics
0.00
3.18
3.18
3.04
0.00
Sales & Valuation
-$
0.00
1.23
-0.49
-4.76
Profitability
-$11.93
-$7.98M
0.00%
0.00%
-162.83%
-148.66%
P/E Metrics
-0.34
0.00
0.00
Analyst Price Target & Rating
$7.00
$8.00
$6.00
2/5
3 Analysts
-52.30%
Financial Health Scores
-27.71
2/9
$3.29M
$5.23M
$1.51M
-$7.77M
Key Metrics (TTM)
-$1.56M
0.00
0.20
3.18
-162.83%
-202.67%
-180.05%
-215.68%
-1484766 days
Company Executives
| Name | Title |
|---|---|
| Tony Goodman | Chief Operating Officer & Director |
| Julie Saiki | Executive Vice President of Strategy |
| Matthew Davidson | Chief Development Officer & Director |
| Adam D. Cutler | Interim Executive Vice President of Finance & Business |
| Vinay Shah | Chief Financial Officer & Treasurer |
| Cary John Claiborne | Chief Executive Officer, President & Director |
| John R. Martin | Chief Legal Officer |
| Brigitte Robertson | Acting Chief Medical Officer |
| Abel Svitavsky | Controller |
| Andrew Taubman | Vice President of Corporate Development |
Poll Results
No votes yet today — be the first to share your view!
About Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Stock
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia. ...
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
2026-06-16 08:00:00
GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company's newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to them becoming employees of the Company in connection with the closing of its business combination with Azora Therapeutics, Inc. (“Azora”), which was previously announced by the Company on June 11, 2026.
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
2026-06-11 11:43:00
- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
2026-05-11 08:30:00
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2026 first quarter ended March 31, 2026.
Frequently Asked Questions
-
What is the current Adial Pharmaceuticals, Inc. (ADIL) stock price?
-
Adial Pharmaceuticals, Inc.(NASDAQ:ADIL) stock price is $3.339 in the last trading session. During the trading session, ADIL stock reached the peak price of $12 while $1.31 was the lowest point it dropped to. The percentage change in ADIL stock occurred in the recent session was 6.0% while the dollar amount for the price change in ADIL stock was $0.19.
-
ADIL's industry and sector of operation?
-
The NASDAQ listed ADIL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADIL?
-
Tony Goodman | Chief Operating Officer & Director
Julie Saiki | Executive Vice President of Strategy
Matthew Davidson | Chief Development Officer & Director
Adam D. Cutler | Interim Executive Vice President of Finance & Business
Vinay Shah | Chief Financial Officer & Treasurer -
How many employees does ADIL have?
-
Number of ADIL employees currently stands at 5. ADIL operates from 1180 Seminole Trail, Glen Allen, VA 22901, US.
-
Link for ADIL official website?
-
Official Website of ADIL is: https://www.adial.com
-
How do I contact ADIL?
-
ADIL could be contacted at phone #434 422 9800 and can also be accessed through its website. ADIL operates from 1180 Seminole Trail, Glen Allen, VA 22901, US.
-
How many shares of ADIL are traded daily?
-
The average number of ADIL shares traded daily for last 3 months was 460.17K.
-
What is the market cap of ADIL currently?
-
The market value of ADIL currently stands at $3.2M with its latest stock price at $3.339